NY A00500

Establishes a generic drug research and development laboratory and production facility within the State University of New York system to manufacture and distribute generic prescription drugs

Requires all drugs produced by the facility to be sold at a price not exceeding the cost of production for New York residents

Creates the Empire State Biosimilar Insulin Initiative as the facility's first priority, tasking it with developing generic versions of the three most widely used forms of insulin

Mandates the Health Commissioner to immediately partner with non-profit generic drug manufacturers registered with the FDA to produce or distribute at least one generic insulin form until the state facility is operational

Caps the price of insulin produced through these partnerships at $30 per monthly dose for New York residents